盈康生命(300143) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the third quarter was ¥147,343,265.68, representing a year-on-year growth of 8.81%, while year-to-date revenue increased by 4.07% to ¥401,956,565.54[9] - Net profit attributable to shareholders decreased by 30.53% to ¥15,430,187.23, with a year-to-date decline of 42.36%[9] - The company reported a net loss of -81,582,891.49, an improvement from -120,620,632.78 in the previous period[59] - Net profit for the current period was ¥45,500,123.26, down from ¥86,686,024.57 in the previous period, indicating a decline of about 47.5%[82] - Total operating revenue for the current period reached ¥401,956,565.54, an increase from ¥386,218,507.02 in the previous period, representing a growth of approximately 4.5%[82] - Basic earnings per share for the current period was ¥0.07, compared to ¥0.12 in the previous period, showing a decline of about 41.7%[86] - Total comprehensive income for the current period was ¥46,598,415.07, down from ¥88,167,945.37, indicating a decrease of approximately 47.3%[86] Revenue Segments - The medical device segment's revenue grew by 7.46% year-on-year, driven by a strategic shift towards comprehensive tumor treatment solutions[10] - The medical services segment reported a year-on-year revenue increase of 3.48%, bolstered by the opening of Changchun Yinkang Hospital in July 2019[11] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,654,254,550.61, an increase of 1.21% compared to the previous year[9] - Total liabilities decreased to ¥548,339,153.51 from ¥555,275,731.92, showing a decline of about 1.25%[56] - Current liabilities rose to ¥281,898,347.35 from ¥186,918,894.99, representing an increase of approximately 50.7%[56] - The total assets and total liabilities and owners' equity were reported at ¥2,655,778,399.05 and ¥2,173,111,018.52 respectively[69] - The company’s total current assets rose to ¥274,801,934.53 from ¥256,233,651.67, an increase of approximately 7.3%[63] Cash Flow - Cash flow from operating activities for the current period is 41,593,906.84, down from 86,894,509.17 in the previous period[95] - Cash inflow from sales of goods and services is 376,973,958.46, compared to 354,184,648.33 in the previous period, showing an increase[95] - The ending balance of cash and cash equivalents is 78,245,329.54, compared to 43,057,421.92 in the previous period, indicating improved liquidity[101] Expenses - Total operating costs amounted to ¥326,664,074.67, compared to ¥278,029,120.86 in the previous period, marking an increase of about 17.5%[82] - Financial expenses increased significantly to ¥7,111,633.27 from ¥1,567,055.98 in the previous period, with interest expenses rising to ¥7,487,044.43[69] - The company’s financial expenses rose to ¥22,025,377.66 from ¥1,628,754.44, indicating a substantial increase attributed to higher interest expenses[82] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,181, with the largest shareholder holding 29.05% of the shares[16] - Owner's equity increased to $2,105,915,397.10 from $2,067,154,087.63, marking a growth of approximately 1.88%[59] Strategic Initiatives - The company aims to expand its tumor treatment services nationwide through both organic growth and acquisitions, enhancing its brand recognition[11] - The company is focused on developing a smart medical system based on IoT technology to become a leading provider of comprehensive tumor treatment solutions in China[14] Other Financial Metrics - The weighted average return on equity was 0.74%, down by 1.04% compared to the previous year[9] - Non-recurring losses totaled ¥6,328,370.03, primarily due to increased financial expenses and market expansion costs[12] - The company reported a credit impairment loss of ¥-2,498,601.56, compared to ¥-1,837,650.61 in the previous period[72]